Menu
Innovation Observatory > Reports > Drugs > Lenalidomide (Revlimid) + rituximab for relapsed/refractory follicular lymphoma and marginal zone lymphoma

< Back

Lenalidomide (Revlimid) + rituximab for relapsed/refractory follicular lymphoma and marginal zone lymphoma

Drugs

Cancer and Palliative Care

October 2017


The drug combination of lenalidomide (oral capsules) and rituximab (by intravenous injection) has the potential to be an effective treatment for relapsed or refractory follicular and marginal zone lymphoma. The drug combination is being developed for patients that are eligible for rituximab monotherapy or for patients that need an alternative to standard chemotherapy regimens, where rituximab alone would be considered sub-optimal.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information



Load More Related Posts
Get Alerts